A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

This study has been completed.

First Received: May 18, 2000 Last Updated: November 11, 2005 History of Changes

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00005668

Purpose

To compare the safety and effectiveness of itraconazole oral solution to placebo in the treatment of a pulmonary aspergilloma.

Aspergilloma is a "fungal ball" in the lungs caused by Aspergillus. The infection can spread from the lungs through the blood to other organs.

Aspergilloma can be life-threatening; therefore, an effective treatment is needed.

Condition	Intervention	Phase
Aspergillosis Lung Diseases, Fungal	Drug: Itraconazole oral solution	Phase II

MedlinePlus related topics: Molds

Drug Information available for: Itraconazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Safety/Efficacy Study
Official Title:	A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:	96
Estimated Study Completion Date:	November 2005

Detailed Description:

Patients are randomly selected to receive itraconazole oral solution by mouth or the inactive placebo (oral cyclodextrin solution) twice daily for 12 months.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

You may be eligible for this study if you:

Are 18 years of age or older.
Have been diagnosed with aspergilloma within the last month.
Have (or have a history of) at least one of the following:
1. positive test for Aspergillus species.
2. presence of antibodies to Aspergillus.
Are willing to participate in the study for 2 full years.
Are female and not pregnant.
Are not breast-feeding.
Agree to use barrier methods of birth control / contraception during the study and for 30 days after.

Exclusion Criteria:

You will not be eligible for this study if you:

Have a history of allergy to triazole or imidazole drugs.
Are unable to take oral medication.
Are not expected to live for more than a month.
Have had a lung biopsy indicating Aspergillus infection.
Have had radiation therapy within the last 6 months.
Require treatment with certain medications.
Received amphotericin, amphotericin lipid formulation, fluconazole, or itraconazole in the two weeks prior to study entry.
Received chemotherapy within the last 6 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005668

Locations

United States, Alabama
Mary Ellen Bradley
Birmingham, Alabama, United States, 35294

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

More Information

No publications provided

Study ID Numbers:	DMID MSG 37, DMID 96-199, NIH/09021
Study First Received:	May 18, 2000
Last Updated:	November 11, 2005
ClinicalTrials.gov Identifier:	NCT00005668 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Mycoses
Respiratory Tract Infections
Respiratory Tract Diseases
Clotrimazole
Miconazole
Antifungal Agents

Lung Diseases
Tioconazole
Aspergillosis
Hydroxyitraconazole
Itraconazole
Lung Diseases, Fungal

Additional relevant MeSH terms:

Anti-Infective Agents
Antiprotozoal Agents
Aspergillosis
Itraconazole
Hydroxyitraconazole
Pharmacologic Actions
Mycoses

Antiparasitic Agents
Respiratory Tract Diseases
Respiratory Tract Infections
Lung Diseases
Antifungal Agents
Therapeutic Uses
Lung Diseases, Fungal

ClinicalTrials.gov processed this record on May 07, 2009